{"id":"NCT00546871","sponsor":"Baxalta now part of Shire","briefTitle":"Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects","officialTitle":"Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-10-03","primaryCompletion":"2009-07-01","completion":"2009-09-01","firstPosted":"2007-10-19","resultsPosted":"2012-08-23","lastUpdate":"2021-05-19"},"enrollment":49,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency Diseases (PID)"],"interventions":[{"type":"DRUG","name":"Immune Globulin Intravenous (Human), 10%","otherNames":[]}],"arms":[],"summary":"The purpose of this study is to evaluate the tolerability of IGIV, 10% given subcutaneously and the pharmacokinetics of immunoglobulin G (IgG) following subcutaneous (SC) treatment with IGIV, 10% in subjects with primary immunodeficiency (PID) disorders.","primaryOutcome":{"measure":"Ratio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV, 10% at an Adjusted/Individual Adapted Dose (Part 3b), Expressed as a Percentage","timeFrame":"Week 12 (IV) and week 32 or 33 (SC)","effectByArm":[{"arm":"Participants ≥12 Years Old With PK Data Part 1 and Part 3b","deltaMin":95.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"24 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":["9440877","21424824","34931880"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":49},"commonTop":["HEADACHE","PYREXIA","VOMITING","NAUSEA","INFUSION SITE PAIN"]}}